Vascular targeted radioimmunotherapy with 213Bi - An α-particle emitter

Stephen Kennel, Saed Mirzadeh

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

To destroy both tumor blood vessels and adjacent tumor cells, an α- particle emitter, 213Bi, has been targeted with a monoclonal antibody (MAb) to vessels that feed lung tumors in mice. Animals, bearing approximately 100 EMT-6 carcinomas each of 50-400 cells in size in the lung, that were treated with 120 μCi of 213Bi-MAb 201B were all cured of their disease. Animals treated when tumors were larger (103-104 cells) had extended life spans, but a small number of residual tumors eventually killed the animals. Significant extension of life span was also induced with another tumor model-rat tracheal carcinoma growing in the lungs of SCID mice that were then treated with 136 μCi 213Bi-MAb 201B. These studies indicate that attack of both blood vessels and tumor cells simultaneously is an effective mode of cancer treatment.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalNuclear Medicine and Biology
Volume25
Issue number3
DOIs
StatePublished - Apr 1 1998

Fingerprint

Radioimmunotherapy
Blood Vessels
Vascular Tissue Neoplasms
Monoclonal Antibodies
Neoplasms
Lung
Carcinoma
SCID Mice
Residual Neoplasm
Life Expectancy
Cell Size

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Vascular targeted radioimmunotherapy with 213Bi - An α-particle emitter. / Kennel, Stephen; Mirzadeh, Saed.

In: Nuclear Medicine and Biology, Vol. 25, No. 3, 01.04.1998, p. 241-246.

Research output: Contribution to journalArticle

@article{089ac09720d34e0aa7aa85ddf9588804,
title = "Vascular targeted radioimmunotherapy with 213Bi - An α-particle emitter",
abstract = "To destroy both tumor blood vessels and adjacent tumor cells, an α- particle emitter, 213Bi, has been targeted with a monoclonal antibody (MAb) to vessels that feed lung tumors in mice. Animals, bearing approximately 100 EMT-6 carcinomas each of 50-400 cells in size in the lung, that were treated with 120 μCi of 213Bi-MAb 201B were all cured of their disease. Animals treated when tumors were larger (103-104 cells) had extended life spans, but a small number of residual tumors eventually killed the animals. Significant extension of life span was also induced with another tumor model-rat tracheal carcinoma growing in the lungs of SCID mice that were then treated with 136 μCi 213Bi-MAb 201B. These studies indicate that attack of both blood vessels and tumor cells simultaneously is an effective mode of cancer treatment.",
author = "Stephen Kennel and Saed Mirzadeh",
year = "1998",
month = "4",
day = "1",
doi = "10.1016/S0969-8051(97)00200-X",
language = "English (US)",
volume = "25",
pages = "241--246",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Vascular targeted radioimmunotherapy with 213Bi - An α-particle emitter

AU - Kennel, Stephen

AU - Mirzadeh, Saed

PY - 1998/4/1

Y1 - 1998/4/1

N2 - To destroy both tumor blood vessels and adjacent tumor cells, an α- particle emitter, 213Bi, has been targeted with a monoclonal antibody (MAb) to vessels that feed lung tumors in mice. Animals, bearing approximately 100 EMT-6 carcinomas each of 50-400 cells in size in the lung, that were treated with 120 μCi of 213Bi-MAb 201B were all cured of their disease. Animals treated when tumors were larger (103-104 cells) had extended life spans, but a small number of residual tumors eventually killed the animals. Significant extension of life span was also induced with another tumor model-rat tracheal carcinoma growing in the lungs of SCID mice that were then treated with 136 μCi 213Bi-MAb 201B. These studies indicate that attack of both blood vessels and tumor cells simultaneously is an effective mode of cancer treatment.

AB - To destroy both tumor blood vessels and adjacent tumor cells, an α- particle emitter, 213Bi, has been targeted with a monoclonal antibody (MAb) to vessels that feed lung tumors in mice. Animals, bearing approximately 100 EMT-6 carcinomas each of 50-400 cells in size in the lung, that were treated with 120 μCi of 213Bi-MAb 201B were all cured of their disease. Animals treated when tumors were larger (103-104 cells) had extended life spans, but a small number of residual tumors eventually killed the animals. Significant extension of life span was also induced with another tumor model-rat tracheal carcinoma growing in the lungs of SCID mice that were then treated with 136 μCi 213Bi-MAb 201B. These studies indicate that attack of both blood vessels and tumor cells simultaneously is an effective mode of cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032054632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032054632&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(97)00200-X

DO - 10.1016/S0969-8051(97)00200-X

M3 - Article

C2 - 9620629

AN - SCOPUS:0032054632

VL - 25

SP - 241

EP - 246

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 3

ER -